CN104470523B - 基于咪唑并[1,2‑b]哒嗪的化合物、包含它们的组合物及其使用方法 - Google Patents
基于咪唑并[1,2‑b]哒嗪的化合物、包含它们的组合物及其使用方法 Download PDFInfo
- Publication number
- CN104470523B CN104470523B CN201380021272.3A CN201380021272A CN104470523B CN 104470523 B CN104470523 B CN 104470523B CN 201380021272 A CN201380021272 A CN 201380021272A CN 104470523 B CN104470523 B CN 104470523B
- Authority
- CN
- China
- Prior art keywords
- pyridazin
- imidazo
- mmol
- esi
- butyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CN(CC1)CCN1c(cc1)n[n]2c1ncc2CCC(*)(C=*)C=C* Chemical compound CN(CC1)CCN1c(cc1)n[n]2c1ncc2CCC(*)(C=*)C=C* 0.000 description 10
- VMJOSIVBDZKORJ-UHFFFAOYSA-N COCCNc(cc1)n[n]2c1ncc2-c1ccc(CN)cc1 Chemical compound COCCNc(cc1)n[n]2c1ncc2-c1ccc(CN)cc1 VMJOSIVBDZKORJ-UHFFFAOYSA-N 0.000 description 2
- KLCXZQXKWZZZFJ-UHFFFAOYSA-N Brc1cnc(cc2)[n]1nc2N(CC1)CC1c1ccccc1 Chemical compound Brc1cnc(cc2)[n]1nc2N(CC1)CC1c1ccccc1 KLCXZQXKWZZZFJ-UHFFFAOYSA-N 0.000 description 1
- AXHZALDOTJSHNJ-ZDUSSCGKSA-N CC(C)(C)COC(N(C)[C@@H](CCC1)CN1c(cc1)n[n]2c1ncc2Br)=O Chemical compound CC(C)(C)COC(N(C)[C@@H](CCC1)CN1c(cc1)n[n]2c1ncc2Br)=O AXHZALDOTJSHNJ-ZDUSSCGKSA-N 0.000 description 1
- OQUFRCNMRPWIAQ-UHFFFAOYSA-N CC(C)(C)OC(N(C)CCCNc(cc1)n[n]2c1ncc2Br)=O Chemical compound CC(C)(C)OC(N(C)CCCNc(cc1)n[n]2c1ncc2Br)=O OQUFRCNMRPWIAQ-UHFFFAOYSA-N 0.000 description 1
- BNSHDKKFLUFROV-NSHDSACASA-N CC(C)(C)OC(N1[C@H](CNc(cc2)n[n]3c2ncc3C(F)F)CCC1)=O Chemical compound CC(C)(C)OC(N1[C@H](CNc(cc2)n[n]3c2ncc3C(F)F)CCC1)=O BNSHDKKFLUFROV-NSHDSACASA-N 0.000 description 1
- JTLAHHKMJIUYLJ-UHFFFAOYSA-N CC(C)(C)OC(NCCC(CC1)CCN1c(cc1)n[n]2c1ncc2[Br]=C)=O Chemical compound CC(C)(C)OC(NCCC(CC1)CCN1c(cc1)n[n]2c1ncc2[Br]=C)=O JTLAHHKMJIUYLJ-UHFFFAOYSA-N 0.000 description 1
- IUTHJLKJEQUGMO-PCLIKHOPSA-N CC(C)C/C(/C(N(CC1)CCN1c(cc1)n[n]2c1ncc2[Br]=C)=O)=N\C(OC(C)(C)C)=O Chemical compound CC(C)C/C(/C(N(CC1)CCN1c(cc1)n[n]2c1ncc2[Br]=C)=O)=N\C(OC(C)(C)C)=O IUTHJLKJEQUGMO-PCLIKHOPSA-N 0.000 description 1
- RNFMCGQYFZEJSG-UHFFFAOYSA-N CC(C)OC(N(C)CCCN)=O Chemical compound CC(C)OC(N(C)CCCN)=O RNFMCGQYFZEJSG-UHFFFAOYSA-N 0.000 description 1
- VIQUDSJHQLWHOX-UHFFFAOYSA-N CC(C)OC(N(C)CCCNC(C(F)(F)F)=O)=O Chemical compound CC(C)OC(N(C)CCCNC(C(F)(F)F)=O)=O VIQUDSJHQLWHOX-UHFFFAOYSA-N 0.000 description 1
- MKJDESAHESNBFB-UHFFFAOYSA-N CC(C)OC(N(CC1)CCN1c(cc1)n[n]2c1ncc2-c1ccncc1)=O Chemical compound CC(C)OC(N(CC1)CCN1c(cc1)n[n]2c1ncc2-c1ccncc1)=O MKJDESAHESNBFB-UHFFFAOYSA-N 0.000 description 1
- LIWHKLDQEIIMNN-LBPRGKRZSA-N CC(C)OC(N1[C@H](CNc(cc2)n[n]3c2ncc3C#N)CCC1)=O Chemical compound CC(C)OC(N1[C@H](CNc(cc2)n[n]3c2ncc3C#N)CCC1)=O LIWHKLDQEIIMNN-LBPRGKRZSA-N 0.000 description 1
- BPNFAUURUCCTNK-UHFFFAOYSA-N CC(c1ccc(-c2cnc(cc3)[n]2nc3NCC[N+]([O-])=O)[s]1)=O Chemical compound CC(c1ccc(-c2cnc(cc3)[n]2nc3NCC[N+]([O-])=O)[s]1)=O BPNFAUURUCCTNK-UHFFFAOYSA-N 0.000 description 1
- IUJDDGPQCVWNEB-UHFFFAOYSA-N CC1(CNc(cc2)n[n]3c2ncc3C2=CC=C(CN)CC2)OCCC1 Chemical compound CC1(CNc(cc2)n[n]3c2ncc3C2=CC=C(CN)CC2)OCCC1 IUJDDGPQCVWNEB-UHFFFAOYSA-N 0.000 description 1
- LNTLKLYPACGEEA-FUKCDUGKSA-N CCC1=CNC(C)(C=C2)N1N=C2NC[C@H](CCC1)N1C(OC(C)(C)C)=O Chemical compound CCC1=CNC(C)(C=C2)N1N=C2NC[C@H](CCC1)N1C(OC(C)(C)C)=O LNTLKLYPACGEEA-FUKCDUGKSA-N 0.000 description 1
- XIYSXAISLLZLRF-UHFFFAOYSA-N CCCCN(C)c(cc1)n[n]2c1ncc2-c1ccc(CN)cc1 Chemical compound CCCCN(C)c(cc1)n[n]2c1ncc2-c1ccc(CN)cc1 XIYSXAISLLZLRF-UHFFFAOYSA-N 0.000 description 1
- HPBNNMLQXFFFJE-UHFFFAOYSA-N CCCCNC1=N[n]2c(C3C=C(CCNC4=O)C4=CC3(C)C)cnc2CC1 Chemical compound CCCCNC1=N[n]2c(C3C=C(CCNC4=O)C4=CC3(C)C)cnc2CC1 HPBNNMLQXFFFJE-UHFFFAOYSA-N 0.000 description 1
- KKKIQLDRGXZVAX-UHFFFAOYSA-N CCCCNc(cc1)n[n]2c1ncc2-c1ccc(C=O)cc1F Chemical compound CCCCNc(cc1)n[n]2c1ncc2-c1ccc(C=O)cc1F KKKIQLDRGXZVAX-UHFFFAOYSA-N 0.000 description 1
- BUEKYWBZTUIORT-UHFFFAOYSA-N CCCCNc(cc1)n[n]2c1ncc2-c1ccc(CN)cc1 Chemical compound CCCCNc(cc1)n[n]2c1ncc2-c1ccc(CN)cc1 BUEKYWBZTUIORT-UHFFFAOYSA-N 0.000 description 1
- PZKCEOJKPXSUHT-LJQANCHMSA-N CCCCNc(cc1)n[n]2c1ncc2-c1ccc(CNC([C@@H](CC(C)C)N)=O)cc1 Chemical compound CCCCNc(cc1)n[n]2c1ncc2-c1ccc(CNC([C@@H](CC(C)C)N)=O)cc1 PZKCEOJKPXSUHT-LJQANCHMSA-N 0.000 description 1
- DPKVTHPBNOQJJV-UHFFFAOYSA-N CCCCNc(cc1)n[n]2c1ncc2-c1ccc(CNCCOC)cc1 Chemical compound CCCCNc(cc1)n[n]2c1ncc2-c1ccc(CNCCOC)cc1 DPKVTHPBNOQJJV-UHFFFAOYSA-N 0.000 description 1
- MFFBHRKQBPFBBA-UHFFFAOYSA-N CN(CCNc(cc1)n[n]2c1ncc2-c(cc1)ccc1C(N)=O)C(CC#C)=O Chemical compound CN(CCNc(cc1)n[n]2c1ncc2-c(cc1)ccc1C(N)=O)C(CC#C)=O MFFBHRKQBPFBBA-UHFFFAOYSA-N 0.000 description 1
- IRLNRMCHBNJKPC-UHFFFAOYSA-N CNCCCNC(C(F)(F)F)=O Chemical compound CNCCCNC(C(F)(F)F)=O IRLNRMCHBNJKPC-UHFFFAOYSA-N 0.000 description 1
- OUYMRXGSRAEFES-UHFFFAOYSA-N COc(nccc1)c1-c1cnc(cc2)[n]1nc2NCCOC1CCCC1 Chemical compound COc(nccc1)c1-c1cnc(cc2)[n]1nc2NCCOC1CCCC1 OUYMRXGSRAEFES-UHFFFAOYSA-N 0.000 description 1
- NLHYLXAUNPAPCY-UHFFFAOYSA-N FC(CCCNc(cc1)n[n]2c1ncc2Br)(F)F Chemical compound FC(CCCNc(cc1)n[n]2c1ncc2Br)(F)F NLHYLXAUNPAPCY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261608758P | 2012-03-09 | 2012-03-09 | |
| US61/608,758 | 2012-03-09 | ||
| PCT/US2013/029043 WO2013134219A1 (en) | 2012-03-09 | 2013-03-05 | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104470523A CN104470523A (zh) | 2015-03-25 |
| CN104470523B true CN104470523B (zh) | 2017-07-11 |
Family
ID=48014284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380021272.3A Active CN104470523B (zh) | 2012-03-09 | 2013-03-05 | 基于咪唑并[1,2‑b]哒嗪的化合物、包含它们的组合物及其使用方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US8969565B2 (enExample) |
| EP (1) | EP2822559B1 (enExample) |
| JP (1) | JP6418949B2 (enExample) |
| KR (1) | KR102085121B1 (enExample) |
| CN (1) | CN104470523B (enExample) |
| AR (1) | AR090291A1 (enExample) |
| AU (1) | AU2013230119B2 (enExample) |
| BR (1) | BR112014022271B1 (enExample) |
| CA (1) | CA2866164C (enExample) |
| ES (1) | ES2676826T3 (enExample) |
| IL (1) | IL234485A (enExample) |
| MX (1) | MX347917B (enExample) |
| NZ (1) | NZ630719A (enExample) |
| RU (1) | RU2014140739A (enExample) |
| SG (1) | SG11201405563VA (enExample) |
| TW (1) | TW201341385A (enExample) |
| UY (1) | UY34669A (enExample) |
| WO (1) | WO2013134219A1 (enExample) |
| ZA (1) | ZA201406148B (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2210891A1 (en) * | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
| DK2734205T3 (en) | 2011-07-21 | 2018-06-14 | Tolero Pharmaceuticals Inc | Heterocyclic Protein Kinase Inhibitors |
| DK2834243T3 (en) | 2012-03-09 | 2018-07-23 | Lexicon Pharmaceuticals Inc | Pyrazole [1,5-a] pyrimidine-based compounds, compositions comprising them and methods for their use |
| US8901305B2 (en) | 2012-07-31 | 2014-12-02 | Bristol-Myers Squibb Company | Aryl lactam kinase inhibitors |
| EP2958924B1 (en) | 2013-02-22 | 2016-12-28 | Bristol-Myers Squibb Company | 5h-chromeno[3,4-c]pyridines as inhibitors of adaptor associated kinase 1 (aak1) |
| AR097543A1 (es) * | 2013-09-06 | 2016-03-23 | Lexicon Pharmaceuticals Inc | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
| CN105979950A (zh) | 2013-10-11 | 2016-09-28 | 百时美施贵宝公司 | 吡咯并三嗪激酶抑制剂 |
| ES2702126T3 (es) * | 2013-12-10 | 2019-02-27 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
| WO2015112806A2 (en) * | 2014-01-24 | 2015-07-30 | Tp Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
| ES2701903T3 (es) * | 2014-01-31 | 2019-02-26 | Bristol Myers Squibb Co | Inhibidores de cinasa a base de quinolina |
| TW201620911A (zh) * | 2014-03-17 | 2016-06-16 | 雷西肯製藥股份有限公司 | 銜接子關聯激酶１之抑制劑、包含其之組成物、及其使用方法 |
| WO2016053794A1 (en) * | 2014-09-30 | 2016-04-07 | Bristol-Myers Squibb Company | Quinazoline-based kinase inhibitors |
| WO2016073889A1 (en) | 2014-11-06 | 2016-05-12 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
| EP3215511B1 (en) | 2014-11-06 | 2024-04-17 | Bial-R&D Investments, S.A. | Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders |
| US20180185368A1 (en) | 2014-11-06 | 2018-07-05 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
| EP3292124B1 (en) | 2015-04-10 | 2019-05-22 | Bristol-Myers Squibb Company | 6h-isochromeno[3,4-c]pyridines and benzo[c][1,7]naphthyridin-6-(5h)-ones as adaptor associated kinase 1 (aak1) inhibitors |
| RU2732405C2 (ru) | 2015-07-02 | 2020-09-16 | Тёрнинг Поинт Терапьютикс, Инк. | Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ |
| BR112018000297A2 (pt) | 2015-07-06 | 2018-09-04 | Tp Therapeutics Inc | polimorfo de macrociclo de diarila |
| WO2017015367A1 (en) * | 2015-07-21 | 2017-01-26 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles and uses thereof |
| KR102782807B1 (ko) * | 2015-11-18 | 2025-03-14 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물 |
| WO2017176961A1 (en) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics Inc. | Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| MX388912B (es) | 2016-04-06 | 2025-03-20 | Lysosomal Therapeutics Inc | Compuestos de pirrol[1,2-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos |
| KR20180133461A (ko) | 2016-04-06 | 2018-12-14 | 리소소말 테라퓨틱스 인크. | 피라졸로[1,5-a]피리미디닐 카르복스아미드 화합물 및 의학적 장애의 치료에서의 그의 용도 |
| FI3442977T3 (fi) * | 2016-04-15 | 2023-09-26 | Blueprint Medicines Corp | Aktiviinireseptorin kaltaisen kinaasin estäjät |
| WO2017192931A1 (en) | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| WO2017192930A1 (en) | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| AU2017302019A1 (en) | 2016-07-28 | 2019-02-07 | Turning Point Therapeutics, Inc. | Macrocycle kinase inhibitors |
| GB201617758D0 (en) | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| KR102719387B1 (ko) * | 2017-01-26 | 2024-10-21 | 한미약품 주식회사 | 이미다조피리다진 화합물 |
| SMT202300269T1 (it) * | 2017-03-14 | 2023-09-06 | Daiichi Sankyo Co Ltd | Metodo per produrre un imidazo[1,2-b]piridazina-derivato 3,6-disostituito |
| CN107082828B (zh) * | 2017-05-19 | 2019-09-17 | 暨南大学 | 一种活性氧响应性高分子载体及其制备方法 |
| PT3658148T (pt) | 2017-07-28 | 2024-08-26 | Turning Point Therapeutics Inc | Compostos macrocíclicos e utilizações dos mesmos |
| US10899733B2 (en) | 2017-08-23 | 2021-01-26 | Oregon Health & Science University | Inhibitors of PARPs that catalyze mono-ADP-ribosylation |
| RS63787B1 (sr) | 2017-12-19 | 2022-12-30 | Turning Point Therapeutics Inc | Makrociklična jedinjenja za lečenje bolesti |
| HUE072069T2 (hu) | 2019-02-12 | 2025-10-28 | Sumitomo Pharma America Inc | 2-((1R,4R)-4-((3-(3-(trifluormetil)fenil)imidazo[1,2- b]piridazin-6-il)amino)ciklohexil)propán-2-ol sósavas sójának kristályos formája |
| CN110684028B (zh) * | 2019-10-28 | 2021-10-26 | 上海阿拉丁生化科技股份有限公司 | 一种2，6-二氮杂双环[3，3，0]辛烷类化合物的制备方法 |
| WO2021216757A1 (en) * | 2020-04-21 | 2021-10-28 | The Uab Research Foundation | Rna-binding protein multimerization inhibitors and methods of use thereof |
| KR102590444B1 (ko) * | 2020-10-16 | 2023-10-18 | 김홍렬 | Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 치료용 조성물 |
| KR102590438B1 (ko) * | 2020-10-16 | 2023-10-18 | 김홍렬 | Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 예방 또는 소독용 조성물 |
| WO2022174253A1 (en) * | 2021-02-12 | 2022-08-18 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| WO2022213062A1 (en) | 2021-03-29 | 2022-10-06 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| WO2025250945A1 (en) * | 2024-05-31 | 2025-12-04 | Baerenkraft Therapeutics, Llc. | Pim inhibitors and method of their use |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101594909A (zh) * | 2006-09-07 | 2009-12-02 | 比奥根艾迪克Ma公司 | 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂 |
| CN102186852A (zh) * | 2008-08-12 | 2011-09-14 | 赛诺菲-安万特 | 2-烷基-6-环氨基-3-(吡啶-4-基)咪唑并[1,2-b]哒嗪衍生物、其制备以及其治疗应用 |
| CN102224153A (zh) * | 2008-09-22 | 2011-10-19 | 阵列生物制药公司 | 作为trk激酶抑制剂的取代的咪唑并[1,2-b]哒嗪化合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
| US7750000B2 (en) * | 2005-09-02 | 2010-07-06 | Bayer Schering Pharma Ag | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments |
| US20070078136A1 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| BRPI0718266A2 (pt) | 2006-10-30 | 2014-01-07 | Novartis Ag | Compostos heterocíclicos como agentes anti-inflamatórios. |
| DK2834243T3 (en) | 2012-03-09 | 2018-07-23 | Lexicon Pharmaceuticals Inc | Pyrazole [1,5-a] pyrimidine-based compounds, compositions comprising them and methods for their use |
| HK1199814A1 (en) * | 2012-03-09 | 2015-07-24 | Lexicon Pharmaceuticals, Inc. | Inhibition of adaptor associated kinase 1 for the treatment of pain |
-
2013
- 2013-03-05 RU RU2014140739A patent/RU2014140739A/ru not_active Application Discontinuation
- 2013-03-05 CN CN201380021272.3A patent/CN104470523B/zh active Active
- 2013-03-05 KR KR1020147028073A patent/KR102085121B1/ko active Active
- 2013-03-05 NZ NZ630719A patent/NZ630719A/en unknown
- 2013-03-05 MX MX2014010584A patent/MX347917B/es active IP Right Grant
- 2013-03-05 JP JP2014561020A patent/JP6418949B2/ja active Active
- 2013-03-05 BR BR112014022271-1A patent/BR112014022271B1/pt active IP Right Grant
- 2013-03-05 ES ES13712953.2T patent/ES2676826T3/es active Active
- 2013-03-05 AU AU2013230119A patent/AU2013230119B2/en active Active
- 2013-03-05 EP EP13712953.2A patent/EP2822559B1/en active Active
- 2013-03-05 CA CA2866164A patent/CA2866164C/en active Active
- 2013-03-05 US US13/785,271 patent/US8969565B2/en active Active
- 2013-03-05 SG SG11201405563VA patent/SG11201405563VA/en unknown
- 2013-03-05 WO PCT/US2013/029043 patent/WO2013134219A1/en not_active Ceased
- 2013-03-08 TW TW102108279A patent/TW201341385A/zh unknown
- 2013-03-11 UY UY0001034669A patent/UY34669A/es not_active Application Discontinuation
- 2013-03-11 AR ARP130100764A patent/AR090291A1/es unknown
-
2014
- 2014-08-21 ZA ZA2014/06148A patent/ZA201406148B/en unknown
- 2014-09-07 IL IL234485A patent/IL234485A/en active IP Right Grant
-
2015
- 2015-02-25 US US14/631,097 patent/US20160024093A1/en not_active Abandoned
-
2016
- 2016-04-26 US US15/138,460 patent/US20170057964A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101594909A (zh) * | 2006-09-07 | 2009-12-02 | 比奥根艾迪克Ma公司 | 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂 |
| CN102186852A (zh) * | 2008-08-12 | 2011-09-14 | 赛诺菲-安万特 | 2-烷基-6-环氨基-3-(吡啶-4-基)咪唑并[1,2-b]哒嗪衍生物、其制备以及其治疗应用 |
| CN102224153A (zh) * | 2008-09-22 | 2011-10-19 | 阵列生物制药公司 | 作为trk激酶抑制剂的取代的咪唑并[1,2-b]哒嗪化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014022271B1 (pt) | 2021-09-21 |
| JP6418949B2 (ja) | 2018-11-07 |
| ES2676826T3 (es) | 2018-07-25 |
| UY34669A (es) | 2013-10-31 |
| US20160024093A1 (en) | 2016-01-28 |
| US20170057964A1 (en) | 2017-03-02 |
| BR112014022271A2 (enExample) | 2017-06-20 |
| AU2013230119A1 (en) | 2014-09-25 |
| CA2866164A1 (en) | 2013-09-12 |
| JP2015509534A (ja) | 2015-03-30 |
| HK1203407A1 (en) | 2015-10-30 |
| IL234485A (en) | 2017-02-28 |
| KR102085121B1 (ko) | 2020-03-05 |
| CN104470523A (zh) | 2015-03-25 |
| MX347917B (es) | 2017-05-17 |
| ZA201406148B (en) | 2016-06-29 |
| TW201341385A (zh) | 2013-10-16 |
| NZ630719A (en) | 2017-01-27 |
| EP2822559A1 (en) | 2015-01-14 |
| SG11201405563VA (en) | 2014-10-30 |
| MX2014010584A (es) | 2014-09-18 |
| CA2866164C (en) | 2020-07-07 |
| WO2013134219A1 (en) | 2013-09-12 |
| KR20140138865A (ko) | 2014-12-04 |
| US8969565B2 (en) | 2015-03-03 |
| US20130245021A1 (en) | 2013-09-19 |
| AU2013230119B2 (en) | 2017-02-23 |
| AR090291A1 (es) | 2014-11-05 |
| RU2014140739A (ru) | 2016-04-27 |
| EP2822559B1 (en) | 2018-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104470523A (zh) | 基于咪唑并[1,2-b]哒嗪的化合物、包含它们的组合物及其使用方法 | |
| JP7041198B2 (ja) | Ｊａｋ阻害剤である５－クロロ－２－ジフルオロメトキシフェニルピラゾロピリミジン化合物 | |
| CN104302649B (zh) | 基于吡唑并[1,5‑a]嘧啶的化合物、包含它们的组合物及其使用方法 | |
| CN109311819B (zh) | 异喹啉-3-基甲酰胺类及其制备和其用途 | |
| CN105683188B (zh) | 作为fgfr4抑制剂的稠环二环吡啶基衍生物 | |
| TWI626050B (zh) | 吡唑並［１，５-ａ］嘧啶類之醫藥組成物與用途 | |
| CN103038233B (zh) | 吡啶酮和氮杂吡啶酮化合物及使用方法 | |
| TWI650321B (zh) | 雜環化合物及其使用方法 | |
| CN114728962A (zh) | 血浆激肽释放酶抑制剂及其用途 | |
| US11078198B2 (en) | Spirocyclic compounds as farnesoid X receptor modulators | |
| HK1217659A1 (zh) | 基於咪唑並[1，2-b]噠嗪的化合物、包含它們的組合物及其使用方法 | |
| WO2022111526A1 (zh) | 一种苯环衍生物及其组合物和药学上的应用 | |
| CN117177973A (zh) | 吡啶并[3,2-d]嘧啶化合物及其用于治疗增殖性疾病的用途 | |
| HK1203407B (en) | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof | |
| HK40070593B (en) | Heteroaryl derivative, preparation method therefor, and use thereof | |
| HK40010369B (en) | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors | |
| HK1201257B (en) | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1203407 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1203407 Country of ref document: HK |